Publications by authors named "J C Thelen"

The cell wall of plants and algae is an important cell structure that protects cells from changes in the external physical and chemical environment. This extracellular matrix, composed of polysaccharides and glycoproteins, must be constantly remodeled throughout the life cycle. However, compared to matrix polysaccharides, little is known about the mechanisms regulating the formation and degradation of matrix glycoproteins.

View Article and Find Full Text PDF

The committed step for de novo fatty acid (FA) synthesis is the ATP-dependent carboxylation of acetyl-coenzyme A catalysed by acetyl-CoA carboxylase (ACCase). In most plants, ACCase is a multi-subunit complex orthologous to prokaryotes. However, unlike prokaryotes, the plant and algal orthologues are comprised both catalytic and additional dedicated regulatory subunits.

View Article and Find Full Text PDF

Lipid remodeling plays a critical role in plant response to abiotic stress and metabolic perturbations. Key steps in this process involve modifications of phosphatidylcholine (PC) acyl chains mediated by lysophosphatidylcholine: acyl-CoA acyltransferases (LPCATs) and phosphatidylcholine: diacylglycerol cholinephosphotransferase (ROD1). To assess their importance in lipid homeostasis, we took advantage of the trigalactosyldiacylglycerol1 (tgd1) mutant that exhibits marked increases in fatty acid synthesis and fatty acid flux through PC due to a block in inter-organelle lipid trafficking.

View Article and Find Full Text PDF
Article Synopsis
  • Dupilumab is an effective treatment for moderate-to-severe atopic dermatitis (AD) and severe asthma (SA), but there hasn't been much real-world analysis on its adverse events, particularly those related to the eyes (DAOSD).
  • This study analyzed data from patients with AD and SA receiving dupilumab to compare the prevalence of adverse events, focusing on ocular problems and treatment discontinuation rates.
  • Results showed a higher prevalence of ocular adverse events in AD patients (62.1%), while SA patients experienced more headaches and injection site reactions, underlining the need for physician awareness when prescribing dupilumab to AD patients and emphasizing the effectiveness of ophthalmic treatments for managing eye-related issues.
View Article and Find Full Text PDF